Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU)
This trial has been registered on November 5th, 2024, in the Japan Registry of Clinical Trials as jRCT1031240461 ( https://jrct.mhlw.go.jp/en-latest-detail/jRCT1031240461 ).
Authors
- Keita Sasaki (ORCID: https://orcid.org/0009-0005-5100-3863)
- Katsuyuki Sakanaka (ORCID: https://orcid.org/0000-0002-1590-0250)
- Kota Kawabata (ORCID: https://orcid.org/0009-0006-5057-7985)
- Akinori Watanabe (ORCID: https://orcid.org/0009-0001-2434-8023)
- Haruhiko Fukuda (ORCID: https://orcid.org/0000-0002-6332-4745)
- Hiroya Takeuchi (ORCID: https://orcid.org/0000-0002-3947-0128)
- Satoru Matsuda (ORCID: https://orcid.org/0000-0001-8441-2755)
- Takahiro Tsushima (ORCID: https://orcid.org/0000-0003-3551-7504)
- Ken Kato
- Ryunosuke Machida
Institutions
- Hiroshima University (JP)
- Keio University (JP)
- Kyoto University (JP)
- Hamamatsu University School of Medicine (JP)
- Shizuoka Cancer Center (JP)
- National Cancer Center (US)
- Japan Clinical Cancer Research Organization (JP)
- Kitasato University (JP)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1186/s12885-025-15403-2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00